Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $20.0 million
Deal Type : Public Offering
Aditxt Announces Pricing of $20.0 Million Public Offering
Details : The company intends to use the net proceeds for general corporate purposes, which may include research and development expenses for plasmid DNA-based therapeutics, capital expenditures, working capital and general and administrative expenses.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 16, 2022
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $20.0 million
Deal Type : Public Offering